Phase II Study of Dasatinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2016
At a glance
- Drugs Dasatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Dec 2012 Planned end date changed from 1 Jan 2012 to 1 Jan 2014 as reported by ClinicalTrials.gov.